IP Library › Granted Patent US 12,410,225
Granted Patent B2
US 12,410,225 · App. 17/292,017 · Granted Sep 9, 2025

Modulation of dendritic cell lineages

Inventors: Nikolai Kley (Waltham, MA); Jan Tavernier (Balegem, BE); Anje Cauwels (Merelbeke, BE); Lennart Zabeau (Zwijnaarde, BE); Erik Depla (Zwijnaarde, BE)
Assignees: Orionis Biosciences, Inc; Orionis Biosciences BV; VIB VZW; Universiteit Gent
C07K14/56A61P35/00C07K14/565C07K16/2815C07K16/2818C07K16/2827C07K16/2851C07K16/2896A61K38/00A61K2039/505C07K2317/22C07K2317/31C07K2317/569C07K2317/71C07K2317/73C07K2317/76C07K2319/30C07K2319/33C07K2319/74
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,410,225
App. No.
17/292,017
Granted
Sep 9, 2025
Kind
B2
Abstract

The present invention relates, in part, to agents, chimeric proteins and chimeric protein complexes that bind a plasmacytoid dendritic cell (pDC), e.g. Clec4C and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the pDC, e.g. Clec4C, binding agents, chimeric proteins, or chimeric protein complexes and their use in the treatment of various diseases, including autoimmune diseases.

Claims (74)

1. A chimeric protein comprising:

(a) a targeting moiety comprising a recognition domain which recognizes and binds to C-Type Lectin Domain Family 4 Member C (Clec4C), wherein the recognition domain comprises a single-domain antibody comprising three complementarity determining regions (CDR1, CDR2, and CDR3), wherein:

(i) CDR1 comprises an amino acid sequence selected from any one of SEQ ID NOs: 1237, 1227-1236 and 1238-1288;

(ii) CDR2 comprises an amino acid sequence selected from any one of SEQ ID NO: 1300, 1289-1299 and 1301-1365; and

(iii) CDR3 comprises an amino acid sequence selected from any one of SEQ ID NO: 1375, 1366-1374, and 1376-1399; and

(b) a modified human IFN-α2, said modified human IFN-α2 having one or more mutations that confer improved safety as compared to a wild type human IFN-α2, and

wherein the targeting moiety and modified human IFN-α2 are connected with one or more linkers.

2. The chimeric protein of claim 1 , further comprising one or more additional targeting moieties.

3. The chimeric protein of claim 2 , wherein the one or more additional targeting moieties comprise a recognition domain that recognizes and binds an antigen or receptor on a tumor cell, an immune cell, or a cell, tissue, or organ affected by autoimmune disease.

4. The chimeric protein of claim 2 , wherein the one or more additional targeting moieties recognize and bind one or more of CD8, Clec9A and X-C Chemokine Receptor 1 (XCR1).

5. The chimeric protein of claim 4 , wherein the one or more additional targeting moieties that recognize and bind XCR1 is X-C Chemokine Ligand 1 (XCL1) or X-C Chemokine Ligand 2 (XCL2).

6. The chimeric protein of claim 1 , wherein the single-domain antibody comprises a recombinant heavy-chain-only antibody (VHH) or a shark heavy-chain-only antibody (VNAR).

7. The chimeric protein of claim 6 , wherein the recognition domain comprises a VHH.

8. The chimeric protein of claim 1 , wherein the modified human IFN-α2 comprises one or more mutations conferring reduced affinity or activity for a receptor relative to a wild type human IFN-α2.

9. The chimeric protein of claim 8 , wherein the one or more mutations allow for attenuation of activity.

10. The chimeric protein of claim 8 , wherein the mutation confers reduced affinity or activity that is restorable by attachment to one or more targeting moiety.

11. The chimeric protein of claim 1 , wherein the modified human IFN-α2 comprises one or more mutations at positions selected from R149, R33, R144, A145, L153, and M148 with reference to SEQ ID NO: 46 or SEQ ID NO: 47.

12. The chimeric protein of claim 1 , wherein the targeting moiety comprises one or more of:

a CDR1 comprising the amino acid sequence of SEQ ID NO: 1227 or 1264, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1289 or 1326, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1366;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1227 or 1264, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1290 or 1327, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1367;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1227 or 1264, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1291 or 1328, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1366;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1227 or 1264, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1290 or 1327, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1367;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1227 or 1264, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1289 or 1326, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1366;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1228 or 1265, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1289 or 1326, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1366;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1227 or 1264, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1290 or 1327, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1367;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1227 or 1264, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1290 or 1329, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1367;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1229 or 1264, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1290 or 1330, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1367;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1230 or 1266, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1292 or 1331, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1368;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1230 or 1266, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1292 or 1332, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1368;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1231 or 1267, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1293 or 1333, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1369;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1232 or 1268, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1294 or 1334, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1369;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1231 or 1267, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1295 or 1335, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1370;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1233 or 1267, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1294 or 1334, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1371;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1234 or 1269, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1296 or 1336, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1372;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1234 or 1269, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1297 or 1337, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1372;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1235 or 1270, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1298 or 1338, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1373;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1236 or 1271, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1299 or 1339, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1374;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1237 or 1272, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1300 or 1340, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1375;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1238 or 1272, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1301 or 1341, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1376;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1236 or 1271, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1302 or 1342, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1376;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1239 or 1273, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1303 or 1343, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1377;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1239 or 1273, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1304 or 1344, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1378;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1240 or 1274, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1304 or 1344, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1378;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1241 or 1275, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1305 or 1345, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1379;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1242 or 1275, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1305 or 1345, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1379;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1243 or 1270, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1306 or 1346, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1380;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1235 or 1270, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1307 or 1347, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1381;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1245 or 1270, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1308 or 1348, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1382;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1246 or 1270, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1309 or 1349, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1383;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1247 or 1276, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1310 or 1350, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1384;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1248 or 1277, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1311 or 1351, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1385;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1249 or 1278, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1312 or 1352, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1386;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1250 or 1279, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1313 or 1353, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1387;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1251 or 1280, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1314 or 1354, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1388;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1252 or 1281, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1315 or 1355, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1389;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1253 or 1282, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1316 or 1356, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1390;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1254 or 1283, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1317 or 1357, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1391;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1255 or 1270, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1318 or 1358, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1392;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1256 or 1270, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1319 or 1359, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1393;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1253 or 1282, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1320 or 1360, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1394;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1257 or 1284, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1321 or 1361, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1395;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1258 or 1285, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1322 or 1362, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1396;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1231 or 1267, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1323 or 1363, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1397;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1259 or 1286, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1324 or 1364, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1398;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1260 or 1287, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1325 or 1365, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1399;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1227 or 1264, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1290 or 1327, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1367;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1235 or 1270, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1298 or 1338, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1373;

CDR1 comprising the amino acid sequence of SEQ ID NO: 1231 or 1267, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1323 or 1363, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1397; and

CDR1 comprising the amino acid sequence of SEQ ID NO: 1260 or 1287, a CDR2 comprising the amino acid sequence of SEQ ID NO: 1325 or 1365, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 1399.

13. The chimeric protein of claim 12 , wherein the targeting moiety comprises an amino acid sequence having at least 95% similarity with any one of SEQ ID NOs: 1424, 1400-1423 and 1425-1455.

14. A recombinant nucleic acid encoding the chimeric protein of claim 1 .

15. A host cell comprising the nucleic acid of claim 14 .

16. A method for treating cancer, comprising administering to a patient in need thereof an effective amount of the chimeric protein of claim 1 .

17. A method for treating an autoimmune disease, comprising administering to a patient in need thereof an effective amount of the chimeric protein of claim 1 .

Assignments (1)
CHANGE OF NAME Recorded Jul 30, 2021
From: ORIONIS BIOSCIENCES NV
To: ORIONIS BIOSCIENCES BV
Reel/Frame 057039/0067 →
Continuity (2)
Provisional Application 62757643 · Nov 8, 2018
Related Publication 20220119472A1 · Apr 21, 2022
References Cited (311)
US 3536809A · Applezweig · 1970 [cited by applicant]
US 3598123A · Zaffaroni · 1971 [cited by applicant]
US 3845770A · Theeuwes et al. · 1974 [cited by applicant]
US 3916899A · Theeuwes et al. · 1975 [cited by applicant]
US 4008719A · Theeuwes et al. · 1977 [cited by applicant]
US 4537776A · Cooper · 1985 [cited by applicant]
US 5059595A · Le Grazie · 1991 [cited by applicant]
US 5073543A · Marshall et al. · 1991 [cited by applicant]
US 5120548A · McClelland et al. · 1992 [cited by applicant]
US 5354556A · Sparks et al. · 1994 [cited by applicant]
US 5475096A · Gold et al. · 1995 [cited by applicant]
US 5591767A · Mohr et al. · 1997 [cited by applicant]
US 5639476A · Oshlack et al. · 1997 [cited by applicant]
US 5674533A · Santus et al. · 1997 [cited by applicant]
US 5716946A · DeLuca et al. · 1998 [cited by applicant]
US 5733556A · Schrier et al. · 1998 [cited by applicant]
US 5831012A · Nilsson et al. · 1998 [cited by applicant]
US 5914254A · Mascarenhas et al. · 1999 [cited by applicant]
US 6004746A · Brent et al. · 1999 [cited by applicant]
US 6433157B1 · Shanafelt et al. · 2002 [cited by applicant]
US 6653104B2 · Goldenberg · 2003 [cited by applicant]
US 6794144B1 · Saksela et al. · 2004 [cited by applicant]
US 6818418B1 · Lipovsek et al. · 2004 [cited by applicant]
US 6994982B1 · Watt et al. · 2006 [cited by applicant]
US 7166697B1 · Galanis et al. · 2007 [cited by applicant]
US 7186524B2 · Kolmar et al. · 2007 [cited by applicant]
US 7250297B1 · Beste et al. · 2007 [cited by applicant]
US 7417130B2 · Stumpp et al. · 2008 [cited by applicant]
US 7803907B2 · Stemmer et al. · 2010 [cited by applicant]
US 7838629B2 · Fiedler et al. · 2010 [cited by applicant]
US 7993636B2 · Mayumi et al. · 2011 [cited by applicant]
US 8008449B2 · Korman et al. · 2011 [cited by applicant]
US 8217149B2 · Irving et al. · 2012 [cited by applicant]
US 8354509B2 · Carven et al. · 2013 [cited by applicant]
US 8580266B2 · Sancho-Madrid et al. · 2013 [cited by applicant]
US 8609089B2 · Langermann et al. · 2013 [cited by applicant]
US 8779108B2 · Queva et al. · 2014 [cited by applicant]
US 8907053B2 · Sasikumar et al. · 2014 [cited by applicant]
US 8907065B2 · Hermans et al. · 2014 [cited by applicant]
US 8980267B2 · Grewal et al. · 2015 [cited by applicant]
US 9067991B2 · Beirnaert · 2015 [cited by applicant]
US 9139634B2 · Morrison et al. · 2015 [cited by applicant]
US 9371389B2 · Sakamoto et al. · 2016 [cited by applicant]
US 9492562B2 · Tavernier et al. · 2016 [cited by applicant]
US 9534056B2 · Grewal et al. · 2017 [cited by applicant]
US 9732135B2 · Tavernier et al. · 2017 [cited by applicant]
US 9878014B2 · Tavernier et al. · 2018 [cited by applicant]
US 9914759B2 · Tavernier et al. · 2018 [cited by applicant]
US 9932409B2 · Tavernier et al. · 2018 [cited by applicant]
US 10034919B2 · Tavernier et al. · 2018 [cited by applicant]
US 10035835B2 · Tavernier et al. · 2018 [cited by applicant]
US 10072059B2 · Tavernier et al. · 2018 [cited by applicant]
US 10407480B2 · Tavernier et al. · 2019 [cited by applicant]
US 10640542B2 · Tavernier et al. · 2020 [cited by applicant]
US 10787493B2 · Tavernier et al. · 2020 [cited by applicant]
US 10906985B2 · Kley et al. · 2021 [cited by applicant]
US 10946070B2 · Tavernier et al. · 2021 [cited by applicant]
US 10947288B2 · Tavernier et al. · 2021 [cited by applicant]
US 10988538B2 · Kley et al. · 2021 [cited by applicant]
US 11001631B2 · Tavernier et al. · 2021 [cited by applicant]
US 11084859B2 · Kley et al. · 2021 [cited by applicant]
US 11236141B2 · Kley et al. · 2022 [cited by applicant]
US 11236166B2 · Kley et al. · 2022 [cited by applicant]
US 11246911B2 · Tavernier et al. · 2022 [cited by applicant]
US 11248057B2 · Tavernier et al. · 2022 [cited by applicant]
US 20020004525A1 · Colover · 2002 [cited by applicant]
US 20020022608A1 · Duncan et al. · 2002 [cited by applicant]
US 20020025304A1 · Croze et al. · 2002 [cited by applicant]
US 20040023334A1 · Prior · 2004 [cited by applicant]
US 20040132094A1 · Etzerodt et al. · 2004 [cited by applicant]
US 20040146938A1 · Nguyen et al. · 2004 [cited by applicant]
US 20040157209A1 · Yilmaz et al. · 2004 [cited by applicant]
US 20040209243A1 · Nixon et al. · 2004 [cited by applicant]
US 20080025980A1 · Hardy et al. · 2008 [cited by applicant]
US 20090202527A1 · Panzara et al. · 2009 [cited by applicant]
US 20100003253A1 · Laeremans et al. · 2010 [cited by applicant]
US 20100028330A1 · Collions et al. · 2010 [cited by applicant]
US 20100087630A1 · Oelert et al. · 2010 [cited by applicant]
US 20100119446A1 · Grabulovski et al. · 2010 [cited by applicant]
US 20100172868A1 · Morrison et al. · 2010 [cited by applicant]
US 20100239633A1 · Strome et al. · 2010 [cited by applicant]
US 20100297076A1 · Morrison et al. · 2010 [cited by applicant]
US 20110020273A1 · Chang et al. · 2011 [cited by applicant]
US 20110081341A1 · Honjo et al. · 2011 [cited by applicant]
US 20110104112A1 · Morrison et al. · 2011 [cited by applicant]
US 20110224407A1 · Langer et al. · 2011 [cited by applicant]
US 20110262348A1 · Movahedi et al. · 2011 [cited by applicant]
US 20110271358A1 · Freeman et al. · 2011 [cited by applicant]
US 20110274658A1 · Silver et al. · 2011 [cited by applicant]
US 20110318373A1 · Sasikumar et al. · 2011 [cited by applicant]
US 20120039906A1 · Olive · 2012 [cited by applicant]
US 20120114649A1 · Langermann et al. · 2012 [cited by applicant]
US 20120244112A1 · Ast et al. · 2012 [cited by applicant]
US 20130034559A1 · Queva et al. · 2013 [cited by applicant]
US 20130058962A1 · Shoemaker et al. · 2013 [cited by applicant]
US 20130183298A1 · Le et al. · 2013 [cited by applicant]
US 20130230517A1 · Grewal et al. · 2013 [cited by applicant]
US 20130245236A1 · Kroczek · 2013 [cited by applicant]
US 20130309250A1 · Cogswell et al. · 2013 [cited by applicant]
US 20140044738A1 · Langermann et al. · 2014 [cited by applicant]
US 20140271462A1 · Ho et al. · 2014 [cited by applicant]
US 20140328865A1 · Sancho-Madrid et al. · 2014 [cited by applicant]
US 20140348789A1 · Tavernier et al. · 2014 [cited by applicant]
US 20140356353A1 · Queva et al. · 2014 [cited by applicant]
US 20150139951A1 · Grewal et al. · 2015 [cited by applicant]
US 20150265721A1 · Lahoud et al. · 2015 [cited by applicant]
US 20150313965A1 · Pogue et al. · 2015 [cited by applicant]
US 20160075769A1 · Verheesen et al. · 2016 [cited by applicant]
US 20160145325A1 · Verheesen et al. · 2016 [cited by applicant]
US 20170016042A1 · Schellenberger et al. · 2017 [cited by applicant]
US 20170029506A1 · Van Der Vliet et al. · 2017 [cited by applicant]
US 20170327576A1 · Barden et al. · 2017 [cited by applicant]
US 20180186894A1 · Tavernier et al. · 2018 [cited by applicant]
US 20180333465A1 · Tavernier et al. · 2018 [cited by applicant]
US 20180334488A1 · Tavernier et al. · 2018 [cited by applicant]
US 20180334489A1 · Tavernier et al. · 2018 [cited by applicant]
US 20190010119A1 · Tavernier et al. · 2019 [cited by applicant]
US 20190071500A1 · Kley et al. · 2019 [cited by applicant]
US 20190092871A1 · Tavernier et al. · 2019 [cited by applicant]
US 20190144553A1 · Kley et al. · 2019 [cited by applicant]
US 20190194284A1 · Kley et al. · 2019 [cited by applicant]
US 20190202934A1 · Tavernier et al. · 2019 [cited by applicant]
US 20190351021A1 · Tavernier et al. · 2019 [cited by applicant]
US 20190352406A1 · Tavernier et al. · 2019 [cited by applicant]
US 20190367604A1 · Kley et al. · 2019 [cited by applicant]
US 20200071414A1 · Kley et al. · 2020 [cited by applicant]
US 20200087411A1 · Kley et al. · 2020 [cited by applicant]
US 20200231674A1 · Kley et al. · 2020 [cited by applicant]
US 20200255545A1 · Tavernier et al. · 2020 [cited by applicant]
US 20200262884A1 · Tavernier et al. · 2020 [cited by applicant]
RU 2011127226A · 2013 [cited by applicant]
WO WO9102754A1 · 1991 [cited by applicant]
WO WO94000491 · 1994 [cited by applicant]
WO WO9404678A1 · 1994 [cited by applicant]
WO WO9634103A1 · 1996 [cited by applicant]
WO WO9710338A1 · 1997 [cited by applicant]
WO WO9937681A2 · 1999 [cited by applicant]
WO WO0043507A1 · 2000 [cited by applicant]
WO WO01014556A1 · 2001 [cited by applicant]
WO WO0190190A2 · 2001 [cited by applicant]
WO WO02085945A2 · 2002 [cited by applicant]
WO WO03025020A1 · 2003 [cited by applicant]
WO WO2003033720A1 · 2003 [cited by applicant]
WO WO03035694A2 · 2003 [cited by applicant]
WO WO2004041862A2 · 2004 [cited by applicant]
WO WO2006053883A1 · 2006 [cited by applicant]
WO WO2006115800A2 · 2006 [cited by applicant]
WO WO2006121168A1 · 2006 [cited by applicant]
WO WO2007005874A2 · 2007 [cited by applicant]
WO WO2008014612A1 · 2008 [cited by applicant]
WO WO2008071447A2 · 2008 [cited by applicant]
WO WO2009003145A1 · 2008 [cited by applicant]
WO WO2009013484A1 · 2009 [cited by applicant]
WO WO2009039409A1 · 2009 [cited by applicant]
WO WO2009053368A1 · 2009 [cited by applicant]
WO WO2009065561A2 · 2009 [cited by applicant]
WO WO2009089149A1 · 2009 [cited by applicant]
WO WO2009101611A1 · 2009 [cited by applicant]
WO WO2009114335A2 · 2009 [cited by applicant]
WO WO2010027827A2 · 2010 [cited by applicant]
WO WO2010030671A1 · 2010 [cited by applicant]
WO WO2010036918A2 · 2010 [cited by applicant]
WO WO2010036959A2 · 2010 [cited by applicant]
WO WO2010066740A1 · 2010 [cited by applicant]
WO WO2010077634A1 · 2010 [cited by applicant]
WO WO2011020783A2 · 2011 [cited by applicant]
WO WO2011029870A1 · 2011 [cited by applicant]
WO WO2011066342A2 · 2011 [cited by applicant]
WO WO2011066389A1 · 2011 [cited by applicant]
WO WO2012145493A1 · 2012 [cited by applicant]
WO WO2012170072A1 · 2012 [cited by applicant]
WO WO2013010779A1 · 2013 [cited by applicant]
WO WO2013053008A2 · 2013 [cited by applicant]
WO WO2013059885A2 · 2013 [cited by applicant]
WO WO2013107791A1 · 2013 [cited by applicant]
WO WO2013134138A1 · 2013 [cited by applicant]
WO WO2013163689A1 · 2013 [cited by applicant]
WO WO2014093396A1 · 2014 [cited by applicant]
WO WO2015007520A1 · 2015 [cited by applicant]
WO WO2015007536A1 · 2015 [cited by applicant]
WO WO2015007542A1 · 2015 [cited by applicant]
WO WO2015007903A1 · 2015 [cited by applicant]
WO WO2015018528A1 · 2015 [cited by applicant]
WO WO2015112900A1 · 2015 [cited by applicant]
WO WO2016022630A1 · 2016 [cited by applicant]
WO WO2016025385A1 · 2016 [cited by applicant]
WO WO2016061142A1 · 2016 [cited by applicant]
WO WO2016062722A1 · 2016 [cited by applicant]
WO WO2016113555A1 · 2016 [cited by applicant]
WO WO2016113557A1 · 2016 [cited by applicant]
WO WO2016187459A1 · 2016 [cited by applicant]
WO WO2017077382A1 · 2017 [cited by applicant]
WO WO2017134301A1 · 2017 [cited by applicant]
WO WO2017134302A2 · 2017 [cited by applicant]
WO WO2017134306A1 · 2017 [cited by applicant]
WO WO2017134305A1 · 2017 [cited by examiner]
WO WO2017153402A1 · 2017 [cited by applicant]
WO WO2017194782A2 · 2017 [cited by applicant]
WO WO2017194783A1 · 2017 [cited by applicant]
WO WO2018077893A1 · 2018 [cited by applicant]
WO WO2018141964A1 · 2018 [cited by applicant]
WO WO2018144999A1 · 2018 [cited by applicant]
WO WO2008124086A2 · 2018 [cited by applicant]
WO WO2018185284A1 · 2018 [cited by applicant]
WO WO2019032661A1 · 2019 [cited by applicant]
WO WO2019032662A1 · 2019 [cited by applicant]
WO WO2019032663A1 · 2019 [cited by applicant]
WO WO2019148089A1 · 2019 [cited by applicant]
WO WO2019152979A1 · 2019 [cited by applicant]
WO WO2019191519A1 · 2019 [cited by examiner]
WO WO2020033646A1 · 2020 [cited by applicant]
WO WO2021062184A1 · 2021 [cited by applicant]
Cauwels et al (Cancer Research, Jan. 15, 2018, 78:463-474). [cited by examiner]
Caminschi, et al., “The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement,” Blood, vol. 112, No. 8, pp. 3264-3273, 2008. [cited by applicant]
Chen, et al., “Dendritic cell targeted vaccines: Recent progresses and challenges,” Human Vaccines & Immunotherapeutics, vol. 12, No. 3, pp. 612-622, 2015. [cited by applicant]
Dzionek, et al., “BDCA-2, a Novel Plasmacytoid Dendritic Cell-specific Type II C-type Lectin, Mediates Antigen Capture and is a Potent Inhibitor of Interferon α/β Induction,” Journal of Experimental Medicine, vol. 194, … [cited by applicant]
Fatima, et al., “Immunoglobin heavy chain variable region, partial [Lama glama],” National Institute of Biotechnology Information, 2 pages, May 5, 2014. [cited by applicant]
International Search Report & Written Opinion, PCT Application No. PCT/US2019/060291, dated Mar. 13, 2020, 23 pages. [cited by applicant]
McLean, et al., “Modified [cited by applicant]
Moayeri, et al., “Immunoglobin heavy chain variable region, partial [Vicugna pacos],” National Institute of Biotechnology Information, 1 page, Sep. 13, 2015. [cited by applicant]
Tullett, et al., “Targeting CLEC9A delivers antigen to human CD141 [cited by applicant]
Biliouris, et al., “A pre-clinical quantitative model predicts the pharmacokinetics/pharmacodynamics of an anti-BDCA2 monoclonal antibody in humans,” J. of Phamacokinetics and Pharmacodynamics, 2018, vol. 45, pp. 817-82… [cited by applicant]
Fournier, et al., “Improved in vitro and in vivo activity against CD303-expressing tergets of the chimeric 122A2 antibody selected for specific glycosylation patten,” MABS, 2018, vol. 10, No. 4, pp. 651-663. [cited by applicant]
Pellerin, et al., “Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dentritic cell activation through Fc-dependent and Fc-independent mechanisms,” Research Article: EMBO Molecular Medicine,2015, vol. 7, No. 4, pp. 4… [cited by applicant]
Riboldi, et al., “Engagement of BDCA-2 blocks TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells,” Immunobiology, 2009, vol. 214, pp. 868-876. [cited by applicant]
Acres, et al., “Fusokine Interleukin-2/Interleukin-18, a Novel Potent Innate and Adaptive Immune Stimulator with Decreased Toxicity,” Cancer Res., vol. 65, No. 20, pp. 9536-9546, 2005. [cited by applicant]
Alegre, et al., A non-activating “humanized” anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo, Jun. 1994, Transplantation, vol. 57, pp. 1537-1543. (Abstract). [cited by applicant]
An, et al., 2009 mAbs, vol. 1, 2009—Issue 6, pp. 572-579. [cited by applicant]
Atwell, et al., “Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library,” JMB, vol. 270, Issue 1, Jul. 4, 1997, pp. 26-35. [cited by applicant]
Baba, et al., “Identification of CCR6, the Specific Receptor for a Novel Lymphocyte-Directed CC Chemokine LARC,” The Journal of Biological Chemistry, vol. 272, No. 23, pp. 14893-14898, 1997. [cited by applicant]
Barbara, et al., “Dissociation of TNF-α cytotoxic and proinflammatory activities by p55 receptor-and p75 receptor-selective TNF-α mutants,” EMBO Journal, vol. 13, No. 4, pp. 843-850, 1994. [cited by applicant]
Bork, et al., “Go hunting in sequence databases but watch out for the traps.” Trends in Genetics, vol. 12, pp. 125-427, 1996. [cited by applicant]
Bork, “Powers and Pitfalls in Sequence Analysis: The 70% Hurdle,” Genome Research, vol. 10, pp. 398-400, 2000. [cited by applicant]
Borrok, et al., “An Fc-Silenced” IgG1 Format with Extended Half-Life Desingned for Improved Stability, J. of Pharm. Sci., 2017, vol. 106, pp. 1008-1017. [cited by applicant]
Boschert, et al., “Single chain TNF derivatives with individually mutated receptor binding sites reveal differential stoichiometry of ligand receptor complex formation for TNFR1 and TNER2,” Cellular Signalling 22 (7):10… [cited by applicant]
Bremer, et al., “Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists,” Cancer Res. 68: 597-604, 2008. [cited by applicant]
Camacho, et al., “Structure of an Interleukin-1β Mutant With Reduced Bioactivity Shows Multiple Subtle Changes in Conformation That Affect Protein-Protein Recognition,” Biochemistry, vol. 32, No. 34, pp. 8749-8757, 1993. [cited by applicant]
Cao & Suresh, “Bispecific MAb Aided Liposomal Drug Delivery,” Journal of Drug Targeting, 2000, vol. 8, No. 4, pp. 257-266, DOI: 10.3109/10611860008997904 (Abstract). [cited by applicant]
Carmenate, et al., “Human IL-2 Mutein with Higher Antitumor Efficacy Than Wild Type IL-2,” The Journal of Immunology, May 2013, vol. 190, pp. 6230-6238. [cited by applicant]
Chapman, “PEGylated antibodies and antibody fragments for improved therapy: a review,” Advanced Drug Delivery Reviews, vol. 54, Issue 4, pp. 531-545 (2002). [cited by applicant]
Chen, et al., “Fusion Protein Linkers: Property, Design and Functionality,” Adv Drug Deliv Rev., Oct. 15, 2013, vol. 65, No. 10, pp. 1357-1369. doi:10.1016/j.addr.2012.09.039. [cited by applicant]
Chichili, et al., “Linkers in the structural biology of protein-protein interactions,” Protein Sci., 2013, vol. 22, pp. 153-167. [cited by applicant]
Choi, et al., “Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma,” PNAS, Jan. 2, 2013, vol. 110, No. 1, pp. 270-275. [cited by applicant]
Couch, et al., “Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier,” Sci. Transl. Med., May 1, 2013, vol. 5, Issue 183, pp. 183ra57. (. [cited by applicant]
Coulstock, et al., “Liver-Targeting of Interferon-Alpha with Tissue Specific Domain Antibodies,” PLOS One, vol. 8, No. 2, pp. 1-11, 2013. [cited by applicant]
Crasto, et al., “LINKER: a program to generate linker sequences for fusion proteins,” Protein Eng., 2000, vol. 13, No. 5, pp. 309-312. [cited by applicant]
De Bruyn, et al., “Antibody-Based Fusion Proteins to Target Death Receptors in Cancer,” Cancer Letters, vol. 332, pp. 175-183, 2013. [cited by applicant]
Deffar, et al., “Nanobodies—The New Concept in Antibody Engineering,” African Journal of Biotechnology, vol. 8, No. 12, pp. 2645-2652, 2009. [cited by applicant]
Dijkmans, et al., “Murine Interferon-γ Interleukin-1 Fusion Proteins Used as Antigens for the Generation of Hybridomas Producing Monoclonal Anti-Interleukin-1 Antibodies,” Cytokine, vol. 3, No. 2, pp. 134-140, 1991. [cited by applicant]
Dimitrov, “Engineered CH2 Domains (Nanoantibodies),” mAbs, Landes Bioscience, vol. 1, No. 1, pp. 26-28, 2009. [cited by applicant]
Frey, et al., “Antibody-Based Targeting of Interferon-Alpha to the Tumor Neovasculature: A Critical Evaluation,” Integrative Biology, vol. 3, pp. 468-478, 2011. [cited by applicant]
Garcin, et al., “High Efficiency cell-specific targeting of cytokine activity,” Nature Communications, vol. 5, No. 8, 9 pages, 2014. [cited by applicant]
Garlanda, et al., “The Interleukin-1 Family: Back to the Future,” Immunity, 39 (6): pp. 1003-1018, Dec. 12, 2013. [cited by applicant]
Gennaro, Remington: The Science and Practice of Pharmacy—19 [cited by applicant]
Gilliland, et al., “Antibody-directed cytotoxic agents: Use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells,” Proc. Nat'l Acad. Sci. USA, 1980, vol. 77, No. 8, pp. 4539-4543. [cited by applicant]
Groopman, et al.,“Chemotherapy-Induced Anemia in Adults: Incidence and Treatment,” J. Natl Cancer Inst., 1999, vol. 91, No. 19, pp. 1616-1634. [cited by applicant]
Gunasekaran, et al., “Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects,” The Journal of Biological Chemistry, 2010, vol. 285, No. 25, pp. 19637-19646. [cited by applicant]
Hamid, et al. “Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma,” The New England Journal of Medicine, 2013, vol. 369, pp. 134-144. [cited by applicant]
Harris, et al., “Effect of pegylation on pharmaceuticals,” [cited by applicant]
Hezareh, et al., “Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type1,” J. Virol. m Dec. 2001, vol. 75, No. 24, pp. 12161-12168. [cited by applicant]
Holler, et al., “Two Adjacent Trimeric Fas Ligands are Required for Fas Signaling and Formation of a Death-Inducing Signaling Complex,” Molecular and Cellular Biology, vol. 23, No. 4, pp. 1428-1440, 2003. [cited by applicant]
Huang, et al., “A Trimeric Anti-HER2/neu ScFv and Tumor Necrosis Factor-[alpha] Fusion Protein Induces HER2/Neu Signaling and Facilitates Repair of Injured Epithelia,” The Journal of Pharmacology and Experimental Therap… [cited by applicant]
Idoyaga, et al., “Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A,” PNAS, vol. 108, No. 6, pp. 2384-2389, Jan. 24, 20… [cited by applicant]
Idusogie, et al.,“Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc,” J. Immunolm, 2000, vol. 164, No. 8, pp. 4178-4184. [cited by applicant]
International Search Report & Written Opinion, PCT Application No. PCT/EP2017/052544, dated Jun. 6, 2017, 16 pages. [cited by applicant]
International Search Report & Written Opinion, PCT Application No. PCT/US2018/045742, dated Dec. 6, 2018, 15 pages. [cited by applicant]
International Search Report & Written Opinion, PCT Application No. PCT/US19/15393, dated Jun. 6, 2019, 17 pages. [cited by applicant]
Kircheis, et al., “Biological activity of mutants of human tumour necrosis factor-alpha,” Immunology, pp. 433-438, Jul. 1, 1992. [cited by applicant]
Krippner-Heidenreich, et al., “Single-Chain TNF, a TNF Derivative with Enhanced Stability and Antitumoral Activity,” The Journal of Immunology, vol. 180, pp. 8176-8183, 2008. [cited by applicant]
Krolick, et al., “Selective killing of normal or neoplastic B cells by antibodies coupled to the A chain of ricin,” Proc. Nat'l Acad. Sci. USA, vol. 77, No. 9, pp. 5419-5423, Sep. 1980. [cited by applicant]
Labrijn, et al., “Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange,” PNAS, Mar. 26, 2013, vol. 110, No. 13, pp. 5145-5150. [cited by applicant]
Lahoud, et al., “Targeting Antigen to Mouse Dendritic Cells via Clec9A Induces Potent CD4 T Cell Responses Biased toward a Follicular Helper Phenotype,” The Journal of Immunology, vol. 187, No. 2, pp. 842-850, Jul. 15, … [cited by applicant]
Langer, “New Methods of Drug Delivery,” Science, 1990, vol. 249, Issue 4976, pp. 1527-1533. Abstract. [cited by applicant]
Leaver-Fay, et al., “Computationally Designed Bispecific Antibodies using Negative State Repertoires”, Structure, 2016, vol. 24, Issue 4, pp. 641-651. [cited by applicant]
Lo, et al., “High level expression and secretion of Fc-X fusion proteins in mammalian cells,” Protein Engineering, 1998, vol. 11, No. 6, pp. 495-500. [cited by applicant]
Lo, et al., “Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice,” The Journal of Biological Chemistry, ASBMB, 2017, vol. 292, No. 9, pp. 3900-3908. [cited by applicant]
Loetscher, et al., “Human Tumor Necrosis Factor α (TNFα) Mutants with Exclusive Specificity for 55-kDA or 75-kDa TNF Receptors,” Journal of Biological Chemistry, American Society For Biochemistry and Molecular Biology, … [cited by applicant]
Masci, et al., “New and Modified Interferon alfas: Preclinical and Clinical Data,” Current Oncology Reports, vol. 5, pp. 108-113, 2003. [cited by applicant]
Merchant, et al., “An efficient route to human bispecific IgG,” Nature Biotechnology, 1998, vol. 16, pp. 677-681. Abstract. [cited by applicant]
Minn, “Interferons and the Immunogenic Effects of Cancer Therapy,” Trends In Immunology, vol. 36, No. 11, pp. 725-737, Nov. 1, 2015. [cited by applicant]
Moore, et al., “A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats,” Methods, 2019, vol. 154, pp. 38-50. [cited by applicant]
Ngo, et al., “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox.The Protein Folding Problem and Tertiary Structure Prediction,” Edited by: Mertz et al., (Birkhauser, Boston), pp. 491-495,… [cited by applicant]
Nicolaou, et al., “Calicheamicin θurn:x-wiley:05700833:media:ANIE199401831:tex2gif-stack-1: A Rationally Designed Molecule with Extremely Potent and Selective DNA Cleaving Properties and Apoptosis Inducing Activity,” An… [cited by applicant]
Pan, et al., “Mutation of the IFNAR-1 Receptor Binding Site of Human IFN-α2 Generates Type I IFN Competitive Antagonists,” Biochemistry, vol. 47, pp. 12018-12027, 2008. [cited by applicant]
Patris, et al., “Nanoimmunoassay onto a screen printed electrode for HER2 breast cancer biomarker determination,” Talanta, 2014, vol. 130, pp. 164-170, 2014. [cited by applicant]
Penafuerte, et al., “The Human Ortholog of Granulocyte Macrophage Colony-Stimulating Factor and Interleukin-2 fusion Protein Induces Potent Ex Vivo Natural Killer Cell Activation and Maturation,” Cancer Res, vol. 69, No… [cited by applicant]
Picco, et al., “Targeting DNGR-1 (CLEC9A) with antibody/MUC1 peptide conjugates as a vaccine for carcinomas,” European Journal of Immunology, vol. 44, No. 7, pp. 1947-1955, Apr. 17, 2014. [cited by applicant]
Piehler, et al., “New Structural and Functional Aspects of the Type I Interferon-Receptor Interaction Revealed by Comprehensive Mutational Analysis of the Binding Interface,” Journal of Biological Chemistry, 2000, vol. … [cited by applicant]
Puskas, et al., “Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases,” Immunology, vol. 133, No. 2, pp. 206-220, Jun. 23, 2011. [cited by applicant]
Rafei, et al., “An Engineered GM-CSF-CCL2 Fusokine Is A Potent Inhibitor of CCR2-Driven Inflammation as Demonstrated in a Murine Model of Inflammatory Arthritis,” The Journal of Immunology, vol. 183, pp. 1759-1766, 2009. [cited by applicant]
Rafei, et al., “A MCP1 Fusokine with CCR2-Specific Tumoricidal Activity,” Molecular Cancer, vol. 10, No. 121, pp. 1-11, 2011. [cited by applicant]
Roisman, et al., “Structure of the Interferon-Receptor Complex Determined by Distant Constraints from Double Mutant Cycles and Flexible Docking,” PNAS, vol. 98, No. 23, pp. 13231-13236, 2001. [cited by applicant]
Rovero, et al., “Insertion of the DNA for the 163-171 Peptide of IL 1 II Enables a DNA Vaccine Encoding p185 [cited by applicant]
Sancho, et al., “Identification of a dendritic cell receptor that couples sensing of necrosis to immunity,” Nature, Nature Publishing Group, United Kingdom, vol. 453, No. 7240, pp. 899-903, Apr. 16, 2009. [cited by applicant]
Schlothauer, et al., “Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions,” Protein Engineering, Design and Selection, 2016, vol. 29, Issue 10, pp. 457-466. [cited by applicant]
Schutyser, et al., “The CC Chemokine CCL20 and its Receptor CCR6,” Cytokine & Growth Factor Reviews, vol. 14, pp. 409-426, 2003. [cited by applicant]
Stahl, “Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters,” BioDrugs, 2015, vol. 29, pp. 215-219. DOI 10.1007/s40259-015-0133-6. [cited by applicant]
Strop, et al., “Generating Bispecific Human IgG1 and IgG2 Antibodies from Any Antibody Pair,” JMB, vol. 420, Issue 3, Jul. 13, 2012, pp. 204-219. [cited by applicant]
Tam, et al., “Functional, Biophysical, and Structural Characterization of Human IgG1 and IgG4 Fc Variants with Ablated Immune Functionality,” Open Access Antibodies, 2017, vol. 6, No. 12, pp. 1-34. doi:10.3390/antib6030… [cited by applicant]
Tao and Morrison, “Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region,” J. Immunol, 1989, vol. 143, No. 8, pp. 2595-… [cited by applicant]
Trebing, et al., “CD70-restricted specific activation of TRAILR1 or TRAIL2 using scFv-targeted TRAIL mutants,” Cell Death and Disease, 2014, vol. 5, e1035; doi:10.1038/cddis.2013.555. [cited by applicant]
Vaneycken, et al., “Preclinical Screening of Anti-HER2 Nanobodies for Molecular Imaging of Breast Cancer”, The ASEB Journal, vol. 25, pp. 2433-2446, 2011. [cited by applicant]
Vafa, et al., 2014 Methods, vol. 65, Issue 1, Jan. 1, 2014, pp. 114-126. [cited by applicant]
Veronese and Harris, “Introduction and overview of peptide and protein pegylation,” Adv. Drug Deliv. Rev., 2002, vol. 54, pp. 453-456. [cited by applicant]
Von Kreudenstein, et al., “Improving biophysical properties of a bispecific antibody scaffold to aid developability,” 2013, mAbs, vol. 5, Issue 5, pp. 646-654. Supplemental material—11 pages. [cited by applicant]
Weber, et al., “Single Amino Acid Changes that Render Human IFN-α2 Biologically Active on Mouse Cells,” The EMBO Journal, vol. 6, No. 3, pp. 591-598, 1987. [cited by applicant]
Wells, “Additivity of Mutational Effects in Proteins,” Biochemistry, vol. 29, No. 37, pp. 8509-8517, 1990. [cited by applicant]
Wesolowski, et al., “Single Domain Antibodies: Promising Experimental and Therapeutic Tools in Infection and Immunity,” Med. Microbiol. Immunol., vol. 198, pp. 157-174, 2009. [cited by applicant]
Yang, et al., “Tailoring structure±function and pharmacokinetic properties of single-chain Fv proteins by site-speci® c PEGylation,” Protein Engineering, 2003, vol. 16, No. 10, pp. 761-770. [cited by applicant]
Youle, et al., “Anti-Thy 1.2 monoclonal antibody linked to ricin is a potent cell-type-specific toxin,” Proc. Nat'l Acad. Sci. USA, September 198, vol. 7, No. 9, pp. 5483-5486. [cited by applicant]
Zitvogel, et al., “Type I interferons in anticancer immunity,” The Journal of Immunology, vol. 15, No. 7, pp. 405-141, Jun. 1, 2015. [cited by applicant]